1. Introduction

The regulation of vaccine stockpiling and distribution systems in Morocco is an important component of public health law, pharmaceutical regulation, administrative governance and national emergency preparedness.

Vaccine stockpiling refers to the procurement, preservation and strategic storage of vaccines to ensure that sufficient quantities are available during routine immunisation programmes, epidemics, pandemics and other public health emergencies.

Vaccine distribution refers to the regulated movement of vaccines from manufacturers and importers to national storage facilities, regional depots, hospitals, healthcare centres and authorised vaccination facilities.

Morocco's regulatory framework seeks to achieve five principal objectives:

Ensure uninterrupted availability of essential vaccines.

Maintain vaccine quality, safety and effectiveness during storage.

Prevent illegal distribution, diversion and counterfeit vaccine circulation.

Guarantee equitable access across urban and rural communities.

Establish accountability for public authorities, pharmaceutical establishments and healthcare distributors.

The principal legal foundation is Law No. 17-04 establishing the Code of Medicines and Pharmacy, promulgated by Dahir No. 1-06-151 of 22 November 2006. The framework was subsequently supplemented by Decree-Law No. 2-24-728 of 27 September 2024, which amended the pharmaceutical legislation and supported the development of Moroccan vaccine and pharmaceutical manufacturing capacity.

sante.gov.ma+2

An important distinction is that Morocco's vaccine stockpiling system is governed by several interconnected legal and administrative requirements rather than by one comprehensive statute exclusively dedicated to vaccine reserves.

2. Constitutional and Public Health Foundations

The Moroccan Constitution of 2011 provides the broader foundation for vaccine availability and distribution.

Article 31 recognises the state's responsibility to mobilise available resources to facilitate citizens' access to healthcare, medical care and social protection.

Article 34 addresses the protection of vulnerable populations and the development of policies responding to their needs.

These constitutional principles have implications for vaccine stockpiling.

For example, if a vaccine shortage disproportionately affects remote communities, the authorities must consider the consequences for equitable healthcare access.

The constitutional framework supports several regulatory obligations:

Public authorities must develop effective healthcare policies.

Essential vaccines should be made available through appropriate public health programmes.

Vulnerable populations should receive appropriate protection.

Administrative decisions affecting vaccine allocation should have a legitimate public health justification.

Constitutional protection does not necessarily create an unconditional right to receive every requested vaccine immediately. However, it provides an important standard for assessing public healthcare policies and administrative decisions.

3. Principal Legislative Framework

A. Law No. 17-04: Code of Medicines and Pharmacy

Law No. 17-04 is the central pharmaceutical legislation governing the manufacture, importation, storage, wholesale distribution and sale of medicines in Morocco.

It is particularly important for vaccine stockpiling because vaccines are biological medicinal products requiring specialised quality controls.

Article 26 regulates wholesale distribution of medicines through authorised pharmaceutical wholesale-distribution establishments, subject to the statutory exceptions.

Article 117 establishes the responsibilities of the responsible pharmacist concerning pharmaceutical operations, including:

Storage and warehousing.

Purchase and control of pharmaceutical materials.

Distribution and sale.

Importation and control of imported products.

Pharmacovigilance.

Monitoring and withdrawal of defective batches.

These provisions make pharmaceutical supervision central to vaccine supply-chain governance.

Ma Loi+2

B. Decree-Law No. 2-24-728 of 27 September 2024

This legislative development amended Law No. 17-04.

Its significance includes strengthening the regulatory framework for pharmaceutical products and supporting national vaccine sovereignty.

The associated Government Bill No. 61.24 was adopted by the Moroccan House of Representatives in February 2025.

The policy objective includes developing domestic vaccine manufacturing capacity, reducing dependence on international suppliers and ensuring that imported and domestically manufactured vaccines satisfy recognised quality requirements.

مجلس النواب، البرلمان، المملكة المغربية+1

C. Decree No. 2-07-1064

This decree regulates the exercise of pharmacy and the establishment and operation of pharmacies and pharmaceutical establishments.

It is relevant to the authorisation and supervision of establishments involved in the pharmaceutical supply chain.

D. Public Procurement Regulations

Public vaccine stockpiling frequently involves government procurement contracts.

The applicable public procurement framework includes Decree No. 2-22-431 of 8 March 2023 on public procurement.

Its principles are relevant to:

Competitive procurement.

Transparency.

Equal treatment of bidders.

Financial accountability.

Contract performance.

Quality requirements.

Prevention of procurement irregularities.

Emergency procurement may require special procedures where legally justified, but urgency does not eliminate the need for accountability and appropriate documentation.

4. Institutional Authorities Responsible for Vaccine Stockpiling

Several public institutions participate in the management and regulation of vaccine supplies.

A. Ministry of Health and Social Protection

The Ministry of Health and Social Protection is responsible for national public health policy and immunisation programmes.

Its responsibilities include:

Estimating national vaccine requirements.

Planning vaccine procurement.

Coordinating national and regional vaccine distribution.

Supervising public immunisation programmes.

Monitoring vaccine shortages.

Coordinating responses to epidemics.

Establishing vaccination priorities during public health emergencies.

The Ministry's procurement and supply-management functions are particularly important because vaccine availability depends on accurate forecasting and timely purchasing.

B. Moroccan Agency for Medicines and Health Products (AMMPS)

The Moroccan Agency for Medicines and Health Products (AMMPS) plays a central regulatory role.

Its functions include pharmaceutical regulation, quality supervision and oversight of medicinal products.

An especially important development occurred on 9 February 2026, when AMMPS published a guideline concerning official batch release of human vaccines and sera.

The guideline establishes a framework for:

Verification of vaccine batch documentation.

Examination of manufacturers' certificates of analysis.

Sampling and laboratory testing where necessary.

Regulatory assessment of vaccine batches.

Release, rejection or quarantine decisions.

Consequently, vaccines cannot simply be introduced into the national distribution system without satisfying applicable batch-release requirements.

AMMPS+1

C. National Laboratory for Medicines Control (LNCM)

The National Laboratory for Medicines Control performs important technical functions associated with vaccine quality control.

Its responsibilities include examination of regulatory documentation, verification of certificates and coordination of laboratory testing.

It can support decisions concerning:

Release of vaccine batches.

Rejection of non-compliant batches.

Quarantine of potentially defective products.

Investigation of quality concerns.

This system reduces the risk of distributing vaccines that do not satisfy applicable quality requirements.

D. Institut Pasteur du Maroc

The Institut Pasteur du Maroc has an important role in the vaccine supply chain.

It is authorised to undertake pharmaceutical activities involving the manufacture, importation and commercialisation of vaccines, sera and biological products.

Its activities are subject to Law No. 17-04 and the regulations applicable to industrial pharmaceutical establishments.

Its vaccine portfolio includes products relating to yellow fever, influenza, rabies, tuberculosis and other infectious diseases.

Institut Pasteur du Maroc

5. Regulation of Strategic Vaccine Stockpiling

Strategic vaccine stockpiling involves maintaining sufficient quantities of vaccines for anticipated public health requirements.

Morocco's stockpiling arrangements must be understood through pharmaceutical legislation, public procurement, national immunisation planning and emergency preparedness.

A. National vaccine forecasting

The government must estimate vaccine requirements based on:

Population size.

Birth rates.

Routine immunisation schedules.

Disease prevalence.

Previous vaccination coverage.

Expected outbreaks.

Vaccine wastage rates.

Delivery lead times.

Inaccurate forecasting may result in either insufficient vaccine reserves or excessive inventories.

B. Minimum stock requirements

A properly managed stockpile should maintain an appropriate reserve based on consumption, procurement lead times and emergency risks.

However, it is important not to confuse a recommended inventory-management practice with a statutory obligation.

A universal legally prescribed minimum number of vaccine doses or months of national reserve has not been established by the sources examined.

Authorities should therefore develop evidence-based stock levels for different vaccines.

C. Rotation of stored vaccines

Vaccines have limited shelf lives. Consequently, stock rotation is essential.

The first-expiry-first-out (FEFO) method is particularly suitable.

Under this system:

Vaccines with earlier expiry dates are distributed first.

Newly received products are properly recorded.

Expired vaccines are segregated.

Near-expiry products are monitored.

Unusable inventory is documented and disposed of appropriately.

This approach reduces financial losses and prevents the administration of expired products.

D. Emergency reserves

Emergency vaccine reserves are particularly important during:

Measles outbreaks.

Polio emergencies.

Influenza epidemics.

COVID-19-like pandemics.

Rabies exposure incidents.

Other infectious disease emergencies.

Emergency reserves should be supported by procurement arrangements, reliable storage capacity, distribution planning and arrangements for replenishment.

6. Cold-Chain Management and Vaccine Storage

Mobile Vaccine Clinics for Immunization Campaigns & Public Health

Temperature Data Loggers for Refrigerator Monitoring | ELPRO

ColdGuard | Rural Vaccine Cold-Chain Integrity

11

Cold-chain management is one of the most important aspects of vaccine regulation.

Vaccines are biological products that may lose effectiveness when exposed to unsuitable temperatures, excessive heat, freezing or other damaging environmental conditions.

The regulatory objective is to preserve product quality from manufacture to administration.

A. Temperature control

Vaccine storage conditions must follow the approved product information and manufacturer requirements.

For many routine vaccines, refrigerated storage is generally maintained between 2°C and 8°C. However, some vaccines require frozen or ultra-cold storage, while others have different approved handling conditions.

Therefore, the 2°C–8°C range must not be treated as a universal rule for every vaccine.

B. Temperature monitoring

Storage facilities should maintain:

Appropriate calibrated temperature-monitoring equipment.

Continuous or sufficiently frequent temperature records.

Temperature excursion reports.

Alarm systems where appropriate.

Documented corrective actions.

Backup arrangements for refrigeration failures.

C. Transportation requirements

Vaccine transportation must preserve the approved storage conditions.

Transport operators should ensure:

Appropriate refrigerated vehicles or validated insulated containers.

Properly conditioned coolant materials.

Temperature monitoring throughout transportation.

Protection against accidental freezing.

Documented dispatch and receipt procedures.

Procedures for handling temperature excursions.

D. Temperature excursion management

A temperature excursion occurs when a vaccine is exposed to temperatures outside its approved storage conditions.

The affected stock should be identified and segregated pending an assessment by the responsible pharmaceutical or regulatory personnel.

It should not automatically be distributed or administered.

The assessment should consider:

Duration of exposure.

Maximum or minimum temperature.

Vaccine formulation.

Manufacturer stability information.

Available stability evidence.

Regulatory instructions.

E. The 2026 Good Distribution Practices Guideline

An important current regulatory development is the AMMPS publication of the Good Distribution Practices (GDP/BPD) Guideline on 21 October 2026.

The guideline establishes a reference framework for pharmaceutical wholesale distribution, including:

Quality-management systems.

Responsibilities of personnel.

Storage facilities and equipment.

Transportation conditions.

Traceability.

Returns and complaints.

Suspected falsified medicines.

Product recalls and withdrawals.

Outsourced distribution activities.

Self-inspections.

Although the guideline addresses medicines generally, its distribution-quality requirements are highly relevant to vaccine supply-chain governance.

AMMPS

7. Regulation of Vaccine Procurement and Importation

Morocco may obtain vaccines through domestic production, international manufacturers, authorised importers and other lawful procurement arrangements.

A. Domestic procurement

Domestic production can reduce dependence on international supply chains.

Morocco's vaccine-sovereignty policy seeks to develop manufacturing capacity and improve the country's ability to respond to future emergencies.

However, domestic manufacturing does not exempt vaccines from regulatory authorisation and quality-control requirements.

B. International procurement

International procurement may involve:

Direct agreements with manufacturers.

Public procurement contracts.

International procurement arrangements.

Emergency purchasing mechanisms.

Donations from international partners.

A relevant historical example is Morocco's memorandum of understanding signed on 18 September 2020 for the acquisition of COVID-19 vaccines produced by R-Pharm under an AstraZeneca licence.

The agreement was part of the government's effort to secure sufficient vaccine supplies for the national vaccination programme.

Reino de Marruecos

C. Importation controls

AMMPS published a guideline on the importation and exportation of medicines for human use on 9 May 2026.

It addresses the importation of authorised medicines and specific import authorisations for particular situations, including emergencies and clinical trials.

The purpose is to improve regulatory compliance, traceability and product safety.

AMMPS

D. Procurement accountability

Public procurement must be supported by appropriate records, including:

Tender documentation.

Supplier qualifications.

Contractual delivery requirements.

Product specifications.

Quality certificates.

Payment documentation.

Delivery and acceptance records.

A procurement contract should also address delayed deliveries, product defects, replacement obligations and the consequences of non-performance.

8. Vaccine Distribution and Allocation Systems

Vaccine distribution requires coordination between national authorities, regional health administrations, pharmaceutical establishments and healthcare facilities.

The distribution system generally involves the following stages:

Vaccine distribution chain

1. Manufacturer or authorised supplier

Production, quality documentation and supply

2. Regulatory control

Authorisation, batch verification and official release

3. National storage facilities

Strategic reserves and inventory management

4. Regional distribution centres

Allocation and cold-chain transportation

5. Hospitals and healthcare centres

Local storage and vaccination preparation

6. Eligible beneficiaries

Administration, documentation and follow-up

A. Regional allocation

Distribution decisions should account for population size, epidemiological needs and available healthcare infrastructure.

An allocation system should not favour wealthier urban areas at the expense of remote or underserved communities.

B. Priority groups

During emergencies, vaccine allocation may prioritise:

Healthcare workers.

Older persons.

Individuals at elevated medical risk.

Essential public-service workers.

Communities experiencing outbreaks.

Other groups identified by public health authorities.

Allocation criteria should be medically justified, transparent and consistently applied.

C. Prevention of diversion

Vaccine diversion occurs when products intended for authorised vaccination programmes are unlawfully redirected.

Regulatory safeguards should include:

Batch-level tracking.

Stock reconciliation.

Authorised recipient verification.

Delivery documentation.

Inspection of distribution facilities.

Investigation of unexplained shortages.

D. Recall and withdrawal

If a vaccine batch is defective, contaminated, falsified or otherwise unsafe, the authorities and responsible pharmaceutical establishments must be able to identify and withdraw affected products.

The AMMPS distribution guideline expressly addresses recall and withdrawal procedures.

AMMPS+1

9. Vaccine Safety, Pharmacovigilance and Liability

Stockpiling and distribution are not limited to preserving physical quantities. They also involve protecting patients against defective or unsafe vaccines.

A. Pharmacovigilance

Pharmacovigilance involves detecting, assessing and preventing adverse reactions associated with medicinal products.

For vaccines, monitoring should include:

Reporting suspected adverse reactions.

Recording vaccine batch numbers.

Investigating unusual adverse events.

Identifying possible manufacturing defects.

Communicating safety warnings.

Taking appropriate regulatory action.

B. Government responsibility

The government has responsibility for developing an effective regulatory and public health system.

Potential liability issues may arise where:

Unsafe vaccines are authorised or distributed.

Regulatory inspections are improperly performed.

Vaccine storage requirements are ignored.

Authorities fail to respond appropriately to known safety warnings.

Patients suffer legally recognised injuries attributable to actionable administrative conduct.

C. Pharmaceutical establishment responsibility

Pharmaceutical establishments and responsible pharmacists may face legal consequences for failures involving storage, distribution, quality control and withdrawal of defective products.

Article 117 of Law No. 17-04 is particularly relevant because it places pharmaceutical operations under the effective supervision of a responsible pharmacist.

Ma Loi

10. Important Moroccan Case Laws and Judicial Decisions

An important research qualification is necessary: there is no clearly identified reported Moroccan appellate judgment specifically deciding the legality of national vaccine stockpile quantities, FEFO inventory systems or regional vaccine-distribution allocations.

Nevertheless, several Moroccan judicial decisions provide important principles relevant to vaccine governance, public health emergencies and administrative accountability.

Case 1. Administrative Court of Rabat – AstraZeneca Vaccine Injury Case (2024)

First-instance judgment

Decision: February 2024.

Subject: State liability for alleged adverse effects following COVID-19 vaccination.

The Administrative Court of Rabat ordered the Moroccan State to pay MAD 250,000 in compensation to a woman who experienced serious medical complications following administration of the AstraZeneca COVID-19 vaccine.

The claimant alleged that vaccination caused Guillain-Barré syndrome and related neurological complications.

The court reportedly relied on the theory of liability for risk, under which compensation could be available without proof of administrative fault, provided the necessary damage and causal connection were established.

Legal significance:

This judgment is relevant to vaccine stockpiling and distribution because government responsibility does not necessarily end when vaccines have been procured and distributed.

The authorities must also consider the safety consequences of vaccination programmes.

It raises important questions concerning:

Vaccine authorisation.

Safety monitoring.

Government responsibility.

Medical causation.

Compensation for vaccine-related injuries.

Important subsequent development: The Rabat Administrative Court of Appeal overturned the first-instance judgment on 24 July 2024 and rejected the compensation claim. Therefore, the first-instance ruling must not be presented as the final established legal position.

Hespress Français - Actualités du Maroc+2

Case 2. Rabat Administrative Court of Appeal – AstraZeneca Compensation Appeal (24 July 2024)

Appellate decision

Subject: Reversal of compensation awarded for alleged COVID-19 vaccine complications.

The Rabat Administrative Court of Appeal overturned the first-instance award of MAD 250,000.

The appellate court rejected the claimant's compensation request.

The full reasoning should be consulted before drawing conclusions about the legal test applied. The available reporting confirms the outcome but does not provide sufficient information to establish every legal ground of the decision.

Legal significance:

This decision demonstrates that vaccine-related liability requires careful judicial examination of causation, evidence and the applicable rules of administrative responsibility.

For vaccine distribution authorities, it highlights the importance of:

Accurate batch identification.

Proper vaccination records.

Medical documentation.

Safety reporting.

Reliable regulatory records.

Evidence supporting administrative decisions.

Akherkhabar.ma | جريدة آخر خبر+2

Case 3. Moroccan Court of Cassation – Publication of COVID-19 Emergency Measures (2022)

Subject: Legal publication of measures adopted during the public health emergency.

The Court of Cassation examined a challenge concerning the government's refusal to publish certain COVID-19 emergency measures in the Official Bulletin.

The applicants argued that measures affecting individuals' legal situations, including restrictions and vaccination-pass requirements, should have been formally published.

The Court rejected the challenge.

It distinguished between legislative and regulatory instruments requiring publication and other emergency measures adopted under the statutory emergency framework.

Legal significance:

This decision is relevant to vaccine distribution governance because it demonstrates the importance of legal authority and procedural requirements when governments introduce emergency public health measures.

It also raises questions concerning:

Administrative transparency.

Emergency powers.

Legal certainty.

Public communication.

The legal basis for vaccination-related restrictions.

The judgment does not directly establish rules for vaccine stockpiling or cold-chain management.

Jurisprudence

Case 4. Moroccan Historical Smallpox Vaccination Legislation (1972)

Legal instrument: Dahir No. 1-72-165 of 27 July 1972.

This instrument concerned compulsory smallpox vaccination and revaccination.

It provided a mechanism through which vaccination could be made compulsory during an epidemic or threat of an epidemic.

Although this is legislation rather than a judicial judgment, it provides historical context for the relationship between compulsory immunisation and state public health responsibilities.

Legal significance:

It illustrates the historical use of state powers to control infectious diseases and protect public health.

Its relevance to modern stockpiling lies in the need to ensure sufficient vaccine availability before compulsory or emergency vaccination measures can be implemented.

QanounAI+1

11. International Legal Principles Relevant to Morocco

Morocco's vaccine distribution system should also be understood in the context of international public health standards.

A. International Health Regulations (2005)

The International Health Regulations establish obligations relating to public health surveillance, preparedness and international cooperation.

For Morocco, these principles support:

Emergency vaccine procurement planning.

Preparedness for infectious disease outbreaks.

International information exchange.

Cooperation with the WHO.

Strengthening national public health infrastructure.

B. Right to health

Article 12 of the International Covenant on Economic, Social and Cultural Rights recognises the right to the highest attainable standard of physical and mental health.

The associated obligation to prevent, treat and control epidemic diseases is particularly relevant to vaccine availability.

C. Children's vaccination protection

Article 24 of the Convention on the Rights of the Child requires states to take appropriate measures to combat disease and malnutrition.

This provides an international foundation for maintaining adequate vaccine supplies for childhood immunisation programmes.

12. Major Legal and Regulatory Challenges in Morocco

Despite the existence of pharmaceutical regulation, vaccine stockpiling and distribution systems face several potential challenges.

A. Rural distribution inequality

Remote communities may face difficulties accessing vaccines because of transport limitations, inadequate refrigeration and shortages of healthcare personnel.

A fair distribution framework should incorporate geographical accessibility and public health needs.

B. Dependence on imported vaccines

International supply disruptions can affect national vaccination programmes.

Developing domestic pharmaceutical manufacturing and reliable procurement arrangements can help reduce these vulnerabilities.

C. Storage infrastructure

Insufficient refrigeration, unreliable electricity and poor transport facilities can damage vaccine stocks.

Public authorities should invest in appropriate infrastructure and contingency arrangements.

D. Regulatory coordination

Coordination is required between AMMPS, the Ministry of Health, the LNCM, pharmaceutical establishments and regional healthcare authorities.

Unclear institutional responsibilities can lead to delayed regulatory decisions and supply-chain failures.

13. Recommendations for Strengthening Morocco's Legal Framework

The following reforms could strengthen the national system.

1. Dedicated vaccine stockpile policy

Morocco could establish a comprehensive policy specifying reserve categories, emergency replenishment arrangements and inventory-management responsibilities.

2. Digital vaccine tracking

A national digital platform could record:

Vaccine manufacturer.

Batch number.

Expiry date.

Storage location.

Temperature history.

Distribution destination.

Recall status.

3. Stronger cold-chain enforcement

Regular inspections and independent temperature audits should be incorporated into distribution supervision.

4. Emergency procurement safeguards

Emergency contracts should include clear quality requirements, delivery deadlines, supplier verification and financial audit mechanisms.

5. Equitable allocation standards

Vaccine distribution should consider disease burden, population vulnerability and geographical access.

6. Improved liability mechanisms

The government could examine clearer compensation and administrative review mechanisms for individuals who suffer proven vaccine-related injuries.

7. Domestic manufacturing development

National manufacturing initiatives should be accompanied by strict quality assurance, batch release, regulatory inspection and international cooperation.

14. Conclusion

The regulation of vaccine stockpiling and distribution systems in Morocco is based on an interconnected framework of constitutional healthcare principles, pharmaceutical legislation, procurement regulation, administrative supervision and international public health standards.

Law No. 17-04 provides the principal pharmaceutical foundation. Decree-Law No. 2-24-728 strengthens the broader regulatory framework, while AMMPS's February 2026 vaccine batch-release guideline and October 2026 Good Distribution Practices guideline represent important developments in quality control and distribution governance.

The Moroccan AstraZeneca litigation also demonstrates that vaccine governance can generate significant questions concerning administrative liability, scientific evidence and patient protection.

Ultimately, an effective national vaccine system requires more than purchasing sufficient quantities of vaccines. It requires legally compliant procurement, safe storage, reliable cold-chain transportation, traceability, equitable allocation, pharmacovigilance and effective institutional accountability.

15. Important Legal References and Research Sources

The following sources are particularly useful for further academic research:

Moroccan Ministry of Health – Applicable Pharmaceutical Legislation.

Law No. 17-04 – Code of Medicines and Pharmacy.

AMMPS – Official Vaccine and Serum Batch-Release Guideline, 9 February 2026.

AMMPS – Good Distribution Practices Guideline, 21 October 2026.

AMMPS – Official Batch Release Procedures.

AMMPS – Importation and Exportation Guideline, 2026.

Institut Pasteur du Maroc – Vaccine Distribution and Pharmaceutical Activities.

Legal Agenda – AstraZeneca Vaccine Compensation Appeal, 2024.

Academic research note: The distinction between legislation, administrative guidance and judicial precedent is essential. The 2024 AstraZeneca first-instance award was reversed on appeal. No direct reported judgment specifically regulating Morocco's national vaccine stockpile system has been established from the sources reviewed. This distinction should be maintained in dissertations, journal articles and legal submissions.